Labiotech.eu

News and Trends 5 Aug 2022

Neurocrine to conduct placebo-controlled study to investigate potential new treatment for schizophrenia

A phase 2 clinical trial for the treatment of schizophrenia has been accepted by the US Food and Drug Administration (FDA) and a study can now go ahead. Neurocrine Biosciences received the news and informed its partner Sosei Group Corporation. The approval of the study of NBI-1117568 has triggered a $30 million payment to Sosei. […]

August 5, 2022 - 3 minutesmins - By Liza Laws

News and Trends 5 Aug 2022

Beyond Biotech podcast 8: Biotech Growth Trust, Deep Science Ventures, Endogena Therapeutics, eureKARE

This week’s podcast guests are Laura Fletcher, head of business development and strategic partnerships at Deep Science Ventures; Matthias Steger, CEO of Endogena Therapeutics; Rodolphe Besserve, CEO, and Georges Rawadi, chief of biotech studio development, at eureKARE; and Biotech Growth Trust portfolio manager, Geoff Hsu. Endogena Therapeutics to start clinical stage with treatment for blindness […]

August 5, 2022

News and Trends 5 Aug 2022

Abivax has approval granted to enroll ulcerative colitis patients in two studies

Patients with moderate to severe ulcerative colitis (UC) can now be enrolled onto two phase 3 induction studies for a biotech company’s lead candidate drug. France-based Abivax SA is a phase 3 clinical stage biotech company that focuses on developing therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer. […]

August 5, 2022 - 3 minutesmins - By Liza Laws

News and Trends 4 Aug 2022

Immunis closes $10M financing round

Immunis Inc., a private U.S. biotech company developing a novel treatment for age and disease-related immune decline, has closed a $10 million series A first closing financing led by Remiges Ventures with participation by several other healthcare investment firms. Proceeds will support clinical assessment of Immunis’ immunomodulatory secretome product in an FDA-awarded phase 1/2a clinical […]

August 4, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 4 Aug 2022

First of its kind drug, to reverse effects of cocaine intoxication, awarded grant

An enzyme that efficiently degrades and metabolizes cocaine has been given a ‘cooperative agreement grant’ from the National Institute on Drug Abuse (NIDA) part of the National Institutes of Health. The recombinant enzyme is a double-mutant cocaine esterase 200 mg intravenous (IV) solution and treats cocaine intoxication, which refers to the state of when cocaine […]

August 4, 2022 - 3 minutesmins - By Liza Laws

News and Trends 4 Aug 2022

Sanofi and Innovent Biologics to collaborate on oncology medicines and boost China presence

Sanofi and Innovent Biologics are to collaborate on providing medicines to patients in China with difficult-to-treat cancers. Innovent is a biopharmaceutical company with clinical development capabilities and a broad commercial footprint in China. Both companies said they are committed to accelerating the development and commercialization of two Sanofi key clinical stage oncology assets: Phase III […]

August 4, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 4 Aug 2022

Deal worth $3.7B sealed as Amgen buys biopharma ChemoCentryx

A company producing drugs including TAVNEOS to treat autoimmune diseases, plus others dealing with inflammatory disorders and cancer has been bought by biopharmaceutical company, Amgen for $52 per share. ChemoCentryx and Amgen have entered a definitive agreement worth approximately $3.7 billion. Robert Bradway, chairman and chief executive officer at Amgen, said: “The acquisition of ChemoCentryx […]

August 4, 2022 - 3 minutesmins - By Liza Laws

News and Trends 4 Aug 2022

Novavax starts COVID-19 vaccine trial for children aged six months to 11 years

U.S. biotech company Novavax, Inc., has started its phase 2b/3 Hummingbird global clinical trial. The trial will evaluate the safety, effectiveness (immunogenicity), and efficacy of two doses of the Novavax COVID-19 vaccine (NVX-CoV2373) in younger children aged six months through 11 years, followed by a booster at six months after the primary vaccination series. “We […]

August 4, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 4 Aug 2022

Gilead Sciences set to acquire MiroBio for $405M

California-headquartered Gilead Sciences, Inc. and MiroBio, a privately-held U.K.-based biotech company, have announced the companies have entered into a definitive agreement with Gilead acquiring MiroBio for approximately $405 million in cash, subject to customary adjustments. The acquisition will provide Gilead with MiroBio’s discovery platform and entire portfolio of immune inhibitory receptor agonists. MiroBio’s lead investigational […]

August 4, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 4 Aug 2022

RoslinCT and Lykan Bioscience combine to create cell therapy CDMO

RoslinCT, a cell and gene therapy contract development and manufacturing organization (CDMO) developing life-changing therapies in Edinburgh’s BioQuarter, and Lykan Bioscience, a CDMO focused on cell-based therapies, have entered into a business combination agreement to form a global advanced therapies CDMO. The combined group will offer process development expertise and cGMP manufacturing for a range […]

August 4, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 4 Aug 2022

PolyPid to receive millions for commercialization of infection-fighting drug

A drug to prevent surgical site infections (SSIs) in abdominal and cardiac surgeries in Europe is to be commercialized after two companies entered an exclusive licensing agreement. Israel-based PolyPid Ltd and UK-based ADVANZ PHARMA Corp. announced the agreement for lead drug candidate D-PLEX100 yesterday (August 3). Topline results Under the terms of the agreement, PolyPid will receive […]

August 4, 2022 - 3 minutesmins - By Liza Laws

News and Trends 4 Aug 2022

F2G to push anti-fungal agent with new $70M funding

F2G Ltd, a clinical-stage biopharma company focused on therapies to treat life-threatening rare fungal infections with a high unmet medical need, has announced $70 million of financing. This was co-led by new investors Forbion and Sofinnova Partners, with participation from existing investors, Novo Holdings, Morningside Ventures, Cowen Healthcare Investments and Advent Life Sciences. Nanna Lüneborg […]

August 4, 2022 - 2 minutesmins - By Jim Cornall

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Neurocrine to conduct placebo-controlled study to investigate potential new treatment for schizophrenia

Beyond Biotech podcast 8: Biotech Growth Trust, Deep Science Ventures, Endogena Therapeutics, eureKARE

Abivax has approval granted to enroll ulcerative colitis patients in two studies

Immunis closes $10M financing round

First of its kind drug, to reverse effects of cocaine intoxication, awarded grant

Sanofi and Innovent Biologics to collaborate on oncology medicines and boost China presence

Deal worth $3.7B sealed as Amgen buys biopharma ChemoCentryx

Novavax starts COVID-19 vaccine trial for children aged six months to 11 years

Gilead Sciences set to acquire MiroBio for $405M

RoslinCT and Lykan Bioscience combine to create cell therapy CDMO

PolyPid to receive millions for commercialization of infection-fighting drug

F2G to push anti-fungal agent with new $70M funding

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!